Embryonic Stem Cell research has been an area of immense promise, but there have been few studies which have shown how these cells can benefit patients in real world applications. Embryonic Stem Cells have the ability to turn into any form of adult cell, which opens up the opportunity for incredible medical advances. On the other hand, the field of medical study is still quite new, and the fruits of that research are still largely in the future.
In just the past few days, however, new research was published that is the first of its kind to present the applied use of Embryonic Stem Cells as a medical treatment, with clear and profound results. Embryonic Stem Cells were successfully used to restore some vision in patients that suffer from chronic, degenerative eye conditions.
Eighteen patients were treated with Embryonic Stem Cells, and the treatment effectively enhanced vision in the majority of these patients. These findings are quite miraculous, but a larger scale study needs to be performed to discover the full applications of this treatment, because the original group of participants was so small. Furthermore, the participants need to be followed for a longer period of time to assess the full benefits of the treatment, as they have only been monitored for under two years.
The benefits of Embryonic Stem Cells surprised even the researchers that conducted the study. They provided the Stem Cell Treatments experimentally, but did not have any strong inclination that the treatment would benefit the patients, because their vision loss was so significant and severe.
The lead researcher of the study, Dr. Steven Schwartz, explains that he was simply amazed by the results, and is hopeful that the treatment will continue to benefit the patients, and eventually become a viable treatment for men and women across the country. Dr. Schwartz is a vision specialist from the University of California-Los Angeles. This study was released by The Lancet, one of the preeminent academic journals in Great Britain.
How Did Researchers Treat the Patients for Vision Loss with Embryonic Stem Cells?
Embryonic Stem Cells are hypothesized to work, because they emulate the structure and function of nearby cells when they are implanted into the patient. Embryonic Stem Cells develop in a particular way based upon the signals they receive from the human body. In the case of this particular study, Embryonic Stem Cells were implanted into the retina of patients that had degenerating optical neurons. In doing so, the Embryonic Stem Cells mimicked the normal function of the dying Retina, improving the vision of the patient.
Most researchers that work in vision care and have examined the details of the study find the results exciting, but they also feel that it was important to withhold full judgment until further clinical trials had been conducted.
Dr. Anthony Atala of Wake Forest reiterates that this Stem Cell Vision Study is the first of its kind that explicitly shows how Embryonic Stem Cells can directly benefit the patient.
This study, at its core, is a proof of concept for the potential of Embryonic Stem Cell Therapy. All of the hypotheses in the world don't mean a thing if they aren't able to be converted into actionable medical science. If further studies go on to prove the effectiveness of Embryonic Stem Cells for this purpose, in the future, the range of options will likely expand into other forms of treatment intended to improve outcomes in patients with chronic, degenerative conditions, such as lung disease and heart disease. In addition, there are a variety of other ways in which Embryonic Stem Cells could be effective, including physical rehabilitation.
Why Are Embryonic Stem Cells Such an Important Area of Research?
Embryonic Stem Cell Research is an exciting area of study because of the potentially universal uses that these Stem Cells may offer patients of all kinds. Embryonic Stem Cells contain all of the DNA and information that can be used to make a living, breathing human being, but entirely undifferentiated. As the body of research continues to grow, it becomes more and more clear that these stem cells can be controlled in a way that allows them to develop into any other kind of tissue.
Of course, we are potentially decades away from unlocking the full potential of this treatment, and, until now, Embryonic Stem Cells have never been used to clearly and effectively treat a medical condition. There is hope that these stem cells will one day be able to mitigate the effects of a variety of conditions, such as paralysis, diabetes, and dementia.
This Embryonic Stem Cell Vision Study is the first FDA Study using Embryonic Stem Cells which has yielded unequivocally positive results. The study is truly significant, and even groundbreaking.
What Kind of Vision Impairment did This Study Treat?
The patients that were treated in this study were all afflicted with one of two forms of central vision impairment: Stargardt's Macular Dystrophy and Macular Degeneration, a condition in which the retina starts to degrade, making it harder for the patient to engage their full visual field. These two forms of visual impairment are the most common forms of blindness in the United States, in both children and adults.
These conditions directly impact the ability to focus on objects in one's visual field. Everything simply fades into a blur. The periphery is generally intact, but without central vision, it is impossible to focus or differentiate between objects in any meaningful fashion.
The researchers in this study combined their efforts with Advanced Cell Technology, Incorporated, a Stem Cell Research facility in Marlborough, Massachusetts. In this study, the researchers used undifferentiated Embryonic Stem Cells and converted them into Retinal Pigment Epithelial Cells, which are vital for central vision, and are the cells which deteriorate as a result of the two most common visual impairments in the United States. Using Embryonic Stem Cells, they created over 50,000 of these cells, and implanted them directly into the retina of the participants.
The hypothesis was that the patient's body would use these fresh and healthy epithelial cells to repair the damage which was caused by the body's own cells that had fallen into disrepair. The researchers were not confident that this treatment would work, but considering that the patients had no other recourse to potentially restore their vision, this research did offer them the unique opportunity to potentially experience benefits that no human being had experienced before, with few to no potential drawbacks, even if the procedure was unsuccessful.
None of the researchers believed that these Stem Cells would improve the vision of their patients. The goal of the study was simply to test the safety of the procedure and treatment before moving on to more directed studies. The scientists that conducted this research worried that this treatment could lead to unwanted side-effects. For example, they could not rule out the possibility that the treatment would promote the development of tumors in the patients eyes, or that it could hasten the visual degradation rather than relieve it.
In order to test their theories without putting the vision of the patient at risk, the researchers selected only subjects that had severe vision issues which left them all but blind. This mitigated the potential risks of the treatment to the patient, but it also meant that it significantly reduced the odds, in theory, that the treatment could provide any tangible benefit to the patient. Dr. Schwartz explains that, because of the issues in selecting patients, he and his fellow researchers had little confidence that the treatment could actually lead to real and significant vision improvement.
It's important to look at this study realistically. Although this trial has been incredibly promising, it's still a long way from reaching the market, and there could always be snags along the way. It's important to recognize that Stem Cell Treatments, although they will all but certainly be available for a wide variety of conditions, are still years off from widespread use. It's important that patients understand that this Stem Cell Therapy is not something that's really available to patients at this time, though it will be in the future.
Side Effects of Stem Cell Vision Therapy
Some of the participants did experience issues resulting from the Stem Cell Therapy, mostly because of medications that they had to take to prevent the Immune System from responding negatively to the treatment. Luckily, none of these side-effects were overly problematic, and none of the patients had to suspend treatment. They found that, although the procedure did lead to some side-effects, the patients experienced no issues resulting directly from the Stem Cells.
Effectiveness of Stem Cell Therapy for Vision Loss
The authors of the study reported that, in the end, ten patients experienced a great improvement in their eyesight. Out of eighteen total patients, only one experienced a decline in vision quality, while the final seven patients either experienced no changes in eyesight or slight improvement.
Dr. Schwartz was amazed by the findings. He explains that, some of the patients that experienced these vision conditions had been suffering from deterioration for thirty years or more, without any real improvement, and that the Stem Cell Therapy directly led to improvements that they had never experienced before.
For example, one patient was a rancher that enjoyed riding horses, but, because of his vision problems, could no longer safely do so. After treatment, he could see well enough to go horseback riding safely. Before treatment, riding was far too dangerous, because he was visually unable to see things like fences or differentiate between objects at a distance in any meaningful way. Now, he can go back to his ranch and effectively corral his cattle, while also recognizing nearby dangers and being able to differentiate among objects in the distance with relative accuracy.
A second patient was a business-person that frequently traveled internationally to perform consultations. Vision problems prevented the patient from being able to travel unaccompanied through airports, but the treatment restored the patient's ability to travel without aid. A third patient was a graphic artist that had lost the ability to practice her craft. After treatment, she was able to see details in her furniture that were invisible to her before treatment.
A fourth patient from Santa Rosa, Isabella Beukes, had been unable to see clearly for longer than forty years. After only a few weeks of Stem Cell Treatment, her vision started to improve. In just that short period of time, she was able to see objects on her computer monitor, as well as recognize her clothes by color in the closet. After two years, she is able to go hiking alone in the forest close by her house. She explains that the Stem Cell Treatment impacted her life in a genuinely profound way. It changed her life and afforded her a level of independence that she hadn't felt in decades. She was honored and amazed that she had had the opportunity to participate in such a life-altering study.
Embryonic Stem Cell Research is Still Considered Ethically Questionable by Some
Embryonic Stem Cell Research is not without its detractors. The only way to get these cells is by taking apart an embryo, which, of course, has the potential to develop into a full-fledged human being. Those that feel that life begins at conception are opposed to such research, and feel that destroying embryos is the literal equivalent of ending a child's life. Although an embryo is just a clump of identical cells, many still afford them with this description.
Of course, even if ethical quandaries in the United States slow down research, Stem Cell Research in other countries will continue to grow and expand at a rapid rate, because the United States is unique in the first world with regard to these ethical issues.
When asked about these ethical issues, Dr. Schwartz points out that his goal as a vision specialist is to help people improve their eyesight, and to restore vision to the blind.
Induced Pluripotent Stem Cells Could One Day Replace Embryonic Stem Cells
There is also a push to unlock the secrets of creating new stem cells from the cells of existing patients. Researchers are in the process of learning how to literally, “turn back the clock,” reverting cells to their embryonic state, or a similar state. As of today, researchers have effectively been able to revert cells to a point of early development, but have issues restoring cells to a state identical to that of Embryonic Stem Cells. These cells may one day replace stem cells, allowing patients to use their own cells for regenerative treatment.
Continuing Research
As his prior research has proven that Stem Cells can be effective at restoring for vision in patients with Macular Degeneration and other visual disorders, Dr. Schwartz has expanded the pool of patients which are eligible for treatment, now including patients that still retain some vision, that are suffering from the same degenerative conditions. He has also begun to implant a larger volume of Stem Cells to find out whether more Stem Cells improve the rate of recovery. The success of his UCLA study has prompted expanded Clinical Trials in London, Philadelphia, Miami, and Boston.
- Navigating the hope and hype of regenerative medicine - October 14th, 2024
- Cell and Gene Therapy Investment Ticks Up After Hard Few Years - BioSpace - October 14th, 2024
- Crackdowns on Unproven Stem Cell Therapies Worked Abroad - Medpage Today - October 14th, 2024
- How Regenerative Medicine can help you get out of pain without surgery - WJLA - October 14th, 2024
- Regenity Biosciences Receives 510(k) Clearance for RejuvaKnee, a Groundbreaking Regenerative Meniscus Implant Device to Redefine the Standard of Care... - October 14th, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - BioPharm International - October 14th, 2024
- Mayo Clinic offers unique regenerative medicine procedure for knee and ... - September 13th, 2024
- Regenerative Medicine to the Rescue - Cleveland Clinic - September 13th, 2024
- Regenerative medicine applications: An overview of clinical trials - September 13th, 2024
- The Progression of Regenerative Medicine and its Impact on Therapy ... - September 13th, 2024
- Immune cell injection significantly boosts healing of bone, muscle & skin - September 13th, 2024
- Regenerative Medicine Foundation - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT ... - September 13th, 2024
- Tissue engineering and regenerative medicine approaches in colorectal ... - September 13th, 2024
- Tubular scaffolds boost stem cell-driven bone regeneration in skull defects - Phys.org - September 13th, 2024
- Finding the right path(way) to reduce fat accumulation in the liver - Medical University of South Carolina - September 13th, 2024
- NAMRU EURAFCENT Signs Agreement with Egypt Center for Research and Regenerative Medicine - DVIDS - September 13th, 2024
- BridgeBio Receives FDAs Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program - StockTitan - September 13th, 2024
- BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and... - September 13th, 2024
- Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate - Yahoo Finance - September 13th, 2024
- Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com - September 13th, 2024
- Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H) - Business Wire - September 13th, 2024
- HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials - Longview News-Journal - September 13th, 2024
- Obsidian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OBX-115 for the Treatment of Advanced Melanoma -... - September 4th, 2024
- Regenerative Medicine in Orthopedic Surgery: Expanding Our Toolbox - Cureus - September 4th, 2024
- Somite.ai takes pre-seed to $10M as it eyes to become the OpenAI of stem cell biology - CTech - September 4th, 2024
- Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS) - Yahoo... - September 4th, 2024
- Study Explores Potential Of 3D Printed Regenerative Breast Implants - Forbes - September 4th, 2024
- Nikon Announces New Image Analysis Functions to Empower Drug Discovery Research for Cancer, Neurological Disease, and Regenerative Medicine - PR... - September 4th, 2024
- Trinity researcher scores 800,000 to boost regenerative medicine - SiliconRepublic.com - September 4th, 2024
- Seeing the future: Zebrafish regenerates fully functional photoreceptor cells and restores its vision - EurekAlert - September 4th, 2024
- Regenerative Medicine Industry Projected to Surge to USD 73,084.2 Million by 2033, Growing at an 18.5% CAGR - Future Market Insights - September 4th, 2024
- What is regenerative medicine? | Northwell Health - July 2nd, 2024
- Science Saturday: A regenerative reset for aging - July 2nd, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023
- Active Wound Care Market Rising demand for Skin Substitutes to boost the industry (2023-2033) | CAGR of 5.5% - EIN News - March 21st, 2023
- Veterinary Orthopedic Implants Market is estimated to be 421.3 Million by 2029 with a CAGR of 5.3% - By PMI - EIN News - March 21st, 2023
- ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical... - February 8th, 2023
- A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field - Yahoo Finance - October 15th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 15th, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 15th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 15th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 15th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - GlobeNewswire - October 15th, 2022
- Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022 -... - October 15th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 15th, 2022
- Cell therapy weekly: Ray Therapeutics and Forge Biologics expand partnership - RegMedNet - October 15th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 15th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Business Wire - October 15th, 2022
- The Health Benefits Of Sea Moss, According To Experts - Forbes - October 15th, 2022
- ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of ... - The Bakersfield Californian - October 15th, 2022
- Pain Management & Regenerative Medicine Specialists DFW - September 4th, 2022
- Tissue Engineering and Regenerative Medicine - National Institute of ... - September 4th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov) - September 4th, 2022
- International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review - September 4th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - September 4th, 2022
- Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace - September 4th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 4th, 2022
- TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all... - September 4th, 2022
- Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire - September 4th, 2022
- Can the immortal jellyfish teach us how to reverse aging? - Earth.com - September 4th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - September 4th, 2022
- Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire - September 4th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 4th, 2022
- Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -... - August 19th, 2022
- Pain Relief Treatments: The Benefits of Regenerative Medicine From Head to Toe - 30Seconds.com - August 19th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 19th, 2022
- Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert - August 19th, 2022